Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Euromed’s Presentation of Initial Positive Results on a Human Study Using ABAlife™ Fig Fruit Extract Welcomed at the American Diabetes Association Meeting
  • USA - English


News provided by

Matisse & Merlot

Jul 10, 2018, 07:00 ET

Share this article

Share toX

Share this article

Share toX

Creating the highest quality standardized botanical extracts
Creating the highest quality standardized botanical extracts

(PRWEB) July 10, 2018 -- Euromed USA, a leading manufacturer of therapeutic botanical extracts, is proud to have been selected for inclusion at the prestigious 78th Annual American Diabetes Association meeting in Orlando, Florida. It is rare for a natural ingredient to be invited to make a presentation at the Annual ADA meeting, and Euromed’s fig fruit extract, ABAlife – Abscisic Acid – is one of the first to introduce the metabolic health benefits of ABA to the world. The study presented showed positive results using ABA life on glucose metabolism blood parameters.

Dietary intervention such as ABAlife supplementation in potentially reducing the risk of chronic diseases warrants further scientific examination, following this successful human pilot study. We are pleased to present our initial clinical trial data at the ADA Annual Meeting

Post this

The Company presented a poster on a new human study evaluating the efficacy of ABAlife™ on glucose metabolism blood parameters, particularly the Glycemic Index (GI) and the Insulinemic Index (II). The GI indicates how fast and efficiently the body can metabolize a carbohydrate meal, while the II shows how much insulin the body releases in response to a meal.

The study -- conducted at an Australian University with established expertise in this field -- researched the effects of two (2) different strengths of the active ingredient, abscisic acid (ABA), in ABAlife™ standardized extracts (100 mg and 200 mg) on post-prandial glucose and insulin responses in healthy subjects.

Promising Results
The highest dosage of 200 mg of ABAlife added to a glucose solution lowered overall levels and peaks in blood glucose and insulin between 30 and 120 minutes post-dose, and significantly improved glycemic index (GI) compared to a reference glucose solution alone. The lower dosage was also effective on GI but did not reach statistical significance. Both dosages however, were able to lower significantly the post-prandial Insulinemic Index (II), with the highest dosage indicating more significant values (p< 0.01). A clear dose-response reduction of GI and II was also elucidated from the data. This promising news about Abscisic Acid as found in ABAlife is currently being further researched right now.

Andrea Zangara, Euromed’s Scientific Marketing Manager, presented preliminary data on its patented product, ABAlife, to the conference attendees titled, “Effect of a Novel Ficus Carica L (Fig) Fruit Extract Standardized to Abscisic Acid on the Glycemic and Insulinemic Responses in Healthy Human Subjects.” An electronic version of the poster was also available for viewing and comments on-screen and on- line during the event on June 25th, 2018. The full data are currently being prepared for publication in a scientific journal. Please contact Euromed for further information at http://www.euromed.es or call 877-696-3960 or email Guy(at)euromedusa(dot)com

ABA for Blood Sugar Support
According to the latest U.S. dietary survey, about 92% of the population might have a deficient intake of ABA due to their less than adequate amounts of fruits and vegetables. High glucose concentrations cause the β-pancreatic cells to release ABA, which improves the efficiency of a glucose transporter (Glut 4) to support glucose uptake into cells and enhances insulin efficiency, suggesting an adaptogen beneficial effect of ABA in promoting whole glycemic control and homeostasis. ABA consumed as a dietary supplement will be an aid in improving glucose tolerance in healthy individuals and those seeking health enhancement.

“Dietary intervention such as ABAlife supplementation in potentially reducing the risk of chronic diseases warrants further scientific examination. We are pleased to present our initial clinical trial data at the ADA Annual Meeting,” according to Guy Woodman, Euromed USA General Manager.

About ABAlife™
ABAlife is a proprietary all-natural line of botanical extracts that contain abscisic acid. The first product to be introduced is an extract from fig fruit, Ficus carica L. A long-standing foodstuff of Mediterranean populations, figs grow naturally throughout Spain and have one of the highest concentrations of abscisic acid found in nature. Because the American diets are usually lacking in adequate amounts of fruits and vegetables they may be deficient in ABA, a compound also produced endogenously. Diabetic patients have been found to have suboptimal levels of ABA. ABAlife delivers the scientifically proven health benefits of ABA while avoiding additional calories associated with eating figs.

About Euromed S.A.
Euromed, located in Barcelona, Spain, produces standardized botanical extracts and natural active substances for use in the dietary supplement, pharmaceutical, and food industries. By extracting the necessary phytochemicals, the company is able to guarantee that each batch of its extracts meets the same profile documented in clinical studies to be safe and effective. The company was established by Madaus GmbH and is now owned by The Riverside Company, with its US office located in Bridgeville, Pennsylvania. For additional information about Euromed’s extracts, call 877-696-3960 or email guy(at)euromedusa.com and visit http://www.euromed.es.

Linda Bryer, Matisse & Merlot, http://www.EuromedUSA.com, +1 8315888767, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.